BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form
BDR Pharmaceuticals International has launched Dalbonova Injection for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. This drug will be available as a 500 mg injection.
BDR Pharmaceutical on Tuesday said it has launched its generic version of Apalutamide, used in the treatment of prostate cancer, in India.
BDR Pharma and Varenyam Healthcare have announced the launch of Sugmadex – an innovation, bringing to India a first-of-its-kind drug in over 10 years with novel ?-cyclodextrin neuromuscular block (NMB) reversal properties. Sugmadex (Sugammadex 100mg/ml) is a pioneer in anaesthesia drugs offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular block (NMB), resulting in the removal of anaesthesia effect on the body, the companies said in a joint statement.
Drugmaker BDR Pharma has raised ?685 crore from a consortium of investors led by private equity firm Multiples.
New Delhi: BDR Pharmaceuticals has announced the launch of Furmecil, the first generic in India (popularly known as S-1, which is a combination of three drugs: Tegafur, Gimeracil, and Oteracil) indicated for the treatment of advanced gastric cancer, which has demonstrated high effectiveness with a favourable safety profile.
The Competition Commission has cleared the proposed acquisition of a minority stake in BDR Pharmaceuticals International Pvt Ltd by Multiples Private Equity Fund III and other investors.
BDR Pharma, the Mumbai-based drugmaker that raised around ?750 crore earlier this year from Renuka Ramnath-led private equity (PE) fund Multiples Alternate Asset Management, is gearing up for geographic expansion that include plans to acquire controlling stake in a Belarus government-owned pharma unit.
BDR Pharmaceuticals on Monday said it has launched prostate cancer treatment drug Enzalutamide in 160 mg strength.
Mankind Pharma and BDR Pharmaceuticals have launched oral anti-COVID pill Molulife (Molnupiravir). The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion and distribution is by Mankind Pharma, the companies notified via a joint statement.